Postpartum Depression Market in the United States to grow 30.35% CAGR

Author : John snow | Published On : 05 Mar 2026

DelveInsight Business Research, LLP has released a comprehensive report on the Postpartum Depression (PPD) market. The study offers detailed information on current treatment practices, emerging drugs, and market share of individual therapies. The analysis covers the 7MM (USA, EU5, and Japan) with a forecast period from 2018 to 2030. Sage Therapeutics emerges as the leading player in the Postpartum Depression market, owing to its monopoly and promising positive results of its asset SAGE-217. Key Market Insights Postpartum Depression majorly impacts females; however, a small percentage of males may also experience depression post-pregnancy. The total diagnosed prevalent population of Postpartum Depression in the 7MM was reported to be 1,155,349 in 2020. The total diagnosed PPD prevalent population in the US is estimated to increase at a CAGR of 0.60% during the study period 2018-2030. This increase in prevalence is ascribed to an increase in diagnosis, recognition of the condition, and awareness through physicians and supportive organizations. However, challenges remain regarding evidence-based universal screening and the actual diagnosis of PPD.

Antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy are effective available Postpartum Depression treatment options. The PPD market only has one FDA-approved drug, Zulresso, marketed by Sage Therapeutics. Consequently, the Postpartum Depression market is dominated by Sage Therapeutics. Zulresso has managed to drastically improve response rates compared to conventional therapies with minimal side effects or risks in infants, as lower levels are passed down in breast milk. However, its 60-hour prolonged intravenous infusion has impacted its market growth.

Sage Therapeutics is investigating its SAGE-217, which is expected to be launched in 2022 in the United States PPD market. Marinus Pharmaceuticals was also evaluating its potential epilepsy drug, Ganaxolone in Phase II study; however, the recent announcement of halting their clinical development has given a clear edge to SAGE-217. The current PPD therapeutic market share in the United States is majorly driven by current treatment practices and the expected launch of emerging therapies.

The US Postpartum Depression market is monopolized by selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SRNIs), atypical antidepressants and antipsychotics, and combination therapies. Despite a tremendous rise in antidepressant prescriptions, there is minimal knowledge regarding the trends in the prescription of these drugs by psychiatrists and non-psychiatric specialists.

Download report to understand which drug is going to capture the maximum market share @ Postpartum Depression Market Analysis and Forecast

Postpartum Depression: Overview Postpartum depression (PPD) is the most common non-psychotic complication post-delivery, usually occurring within 1–12 months after delivery. While some women suffer from mild forms, in others, it can take a severe form. Common symptoms include tearfulness, despondency, emotional liability, feelings of guilt, loss of appetite, sleep disturbances, irritability, poor concentration, and memory loss.

Epidemiology Analysis and Segmentation The condition affects approximately 10-15% of women and is a considerable public health concern. It is estimated that around 14–23% of pregnant women experience depression during pregnancy. Several types of depressions affect women after childbirth, including Baby Blues, Postpartum Psychosis, Postpartum OCD, Posttraumatic stress disorder (PTSD), and Postpartum Panic Disorder. DelveInsight estimates that out of all the types of depressions, Postpartum blues or baby blues affect the most women in the 7MM, whereas Postpartum Psychosis accounts for the least cases.

The report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into Total Diagnosed Prevalent Population and Type-specific Diagnosed Prevalence.

Visit for deep insights into the patient pool @ Postpartum Depression Epidemiology Insights and Upcoming Trends

Therapeutics Market Postpartum Depression is managed through interventions for depression, anxiety disorders, alcohol and drug abuse, and psychological interventions for eating disorders. It can be treated with antidepressant medications, CBT, and interpersonal therapy. The current US Postpartum Depression therapeutics market consists of only one FDA-approved product—Zulresso (brexanolone/SAGE-547)—to treat patients with PPD. The drug is an asset of Sage Therapeutics and was approved by the US FDA in March 2019. The therapy has transformed the treatment landscape of PPD without putting the newborn at risk of any side effects.

However, the therapy is not approved in Europe and Japan; rather, no therapy has received recommendations from the respective regulatory agencies for the PPD treatment. Furthermore, ascribed to almost similar signs and symptoms of PPD as that of other depressive disorders, its accurate and timely diagnosis remains a major challenge.

Reach out to us @ Postpartum Depression Marketed Therapies for more information on available treatment regimens

Market Forecast DelveInsight estimates that the outlook of the Postpartum Depression market is anticipated to change in the next decade owing to a better understanding of mental health disorders, discovery of new upcoming therapeutic strategies harnessing the principle of GABAA receptor modulation, improvements in research and development, entry of novel therapies, and an influx of pharma companies during the forecast period of 2021-2030.

Pharmaceutical companies such as Sage Therapeutics, Shionogi & Co., Ltd. (Japan), Ono Pharmaceutical Co., Ltd. (Japan), and TWi Biotechnology, Inc. (Taiwan) are proactively developing therapies to push the Postpartum Depression market share growth. In terms of Emerging therapies, Sage Therapeutics reported positive results of SAGE-217 from its trials conducted in January 2019. Shionogi holds regional rights in Japan, Korea, and Taiwan for Zuranolone (SAGE-217), with Phase 3 trials and NDA submission in Japan in 2024. Ono Pharmaceutical is conducting Phase 2 studies for an undisclosed CNS candidate targeting PPD, including recruitment in Korea and Taiwan (NCT04947319). TWi Biotechnology is developing NORA520, an oral prodrug antidepressant, with Phase 2 enrollment completed (NCT06285916) and results expected in 2025. Until last year, Marinus Pharmaceuticals was evaluating its potential epilepsy drug, Ganaxolone, in Phase II study; however recently, they have announced a halt in their clinical development, giving a clear edge to SAGE-217.

Pipeline Therapies

Zuranolone (SAGE-217): Sage Therapeutics / Shionogi & Co., Ltd.
Ganaxolone: Marinus Pharma (Although development currently on hold)
NORA520: TWi Biotechnology, Inc.

Market Guiding Factors PPD prevalence rates are increasing, ranging from 6.9–12.9% in high-income countries to more than 20% in some low- or middle-income countries, and is a major driving force behind the expansion of the PPD market growth. An increase in R&D and availability of better diagnostic methodologies is further going to propel the growth of the Postpartum Depression market.

The pipeline profile of the PPD is although narrow, however, this gives immense opportunities to pharma players to explore the waters and bridge the treatment gap. However, readily available off-label therapies at cheaper rates are going to hamper the penetration of novel therapies in the PPD market. There is also a need for increased awareness to kill the stigma and misinterpretation around mental health disorders for the betterment of patients.

Check out for more @ Postpartum Depression Market Forecast

The report also covers the present Postpartum Depression treatment practice/algorithm, PPD market drivers, market barriers, and unmet medical needs that help clients curate the best of the opportunities and assess the market's underlying potential, and plans strategically to tackle the Postpartum Depression market risks.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

DelveInsight’s “Postpartum Depression Epidemiology Forecast – 2034” report delivers an in-depth understanding of the Postpartum Depression, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. The leading companies Sage Therapeutics, and others.

Postpartum Depression - Pipeline Insight, 2026

DelveInsight’s, “Postpartum Depression - Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Postpartum Depression pipeline landscape. The leading companies Sage Therapeutics, and others.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: [email protected]

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com